Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

Diseases and Conditions Researched

Kidney Complications, Allograft

What is the purpose of this trial?

This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell injury in the kidney.

The investigators hypothesize that complement inhibition with eculizumab will reduce allograft injury, resulting from less complement-mediated injury of endothelial cells and less endothelial cell activation.


Participation Guidelines

Age: 18 Years - 65 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsors: Alexion Pharmaceuticals; Sanjay Kulkarni
Last Updated:
Study HIC#: 1007007166